Impact of Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis
JAMA Dermatol 2021 Apr 07;[EPub Ahead of Print], N Loft, A Egeberg, MK Rasmussen, LE Bryld, CV Nissen, TN Dam, KK Ajgeiy, L Iversen, L SkovFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.